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S100A2 gene products were shown to be frequently and dramatically over-represented in non-small cell lung cancer (NSCLC)
lesions over normal tissue by microarray analysis. We have now analysed an independent series of NSCLC tumours and multiple
matched normal bronchial epithelial sites by RT–PCR and immunohistochemistry to investigate: whether this expression pattern can
be confirmed and whether elevated expression is associated with tumour histology, clinical outcome or preneoplasia. In this second
series, S100A2 was strongly expressed in 76% (35 out of 46) of tumours, more frequently in squamous cell than adenocarcinomas
(Po0.002). This strong expression was not related to high-level gene amplification, but was associated in one of five informative cases
with an allele-specific imbalance in transcript levels. Most tumours strongly expressed the DNp63 transcript, the product of which is a
putative regulator of S100A2 transcription and while all but one of the tumours positive for DNp63 expressed S100A2, others
negative for this regulator also expressed the gene. Contrary to the hypothesis that S100A2 is a tumour suppressor, no somatic
mutations were identified in the coding sequence in 44 tumours. Furthermore, an examination of multiple tumour-free epithelial sites
from 20 patients showed that strong expression was often associated with increasing levels of disorder in preinvasive bronchial
lesions (Po0.0001).
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Lung cancer is the leading cause of cancer-related death. The
5-year survival rate in Europe is poor, remaining at approximately
10% (Bray et al, 2002). This is a consequence of a generally late
presentation coupled with an inability to treat disseminated
disease effectively. It has been hypothesised that the early
presymptomatic detection of lung cancer and early intervention
would significantly reduce associated mortality. However, we must
bear in mind that it is unlikely that the use of conventional, toxic
chemotherapeutic agents or radical surgery will be justified unless
a certainty of future life-threatening disease can be established.
Successful early detection methods will therefore need to be
coupled to minimally toxic treatment (chemoprevention) strate-
gies. The examination of the expression of particular genes in
tumour compared to normal cells is one way in which new disease
biomarkers and novel therapeutic targets can be identified.
Dual-channel cDNA microarray analysis of relative expression in
39 primary non-small cell lung carcinomas (NSCLC) compared to
matched normal tissue was used to construct ranked lists of the
most frequently and dramatically differentially expressed genes
(Heighway et al, 2002). One of the sequences so highlighted,
S100A2, a gene considered to be a tumour suppressor, was found to
be over-represented in tumour samples compared to matched
normal lung. S100A2 is one of a family of calcium binding proteins
characterised by two conserved calcium binding EF-hand domains
(Donato, 1999). The S100A2 gene is located within the epidermal
differentiation complex (EDC) on chromosome 1q21 and is in a
region that is frequently rearranged in many types of human cancer
(Ilg et al, 1996), including NSCLC (Whang-Peng et al, 1991).
Originally discovered through subtractive hybridisation, S100A2
was reportedly downregulated in malignant breast epithelial cells
compared to normal mammary epithelial cells (Lee et al, 1991).
Apparent under-representation or downregulation of the gene
product in breast cancer cells relative to normal breast epithelia has
subsequently been confirmed by a number of groups (Pedrocchi
et al, 1994; Wicki et al, 1997; Liu et al, 2000). Diminished S100A2
expression has also been described in a cell line model study of
early lung cancer (Feng et al, 2001) and a number of other cancers,
including head and neck cancer (Nagy et al, 2001) and skin
melanoma (Maelandsmo et al, 1997). Conversely, in addition to our
analysis of NSCLC, over-representation of S100A2 has also been
reported in gastric cancer (El-Rifai et al, 2002) ovarian cancer
(Hough et al, 2001) and head and neck cancer (Villaret et al, 2000).
At a superficial level, these results appear to suggest contra-
dictory patterns of gene expression between different tissues and
diseases and in some cases, between different centres. There is
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ylittle doubt (based on our earlier transcript and protein-based
analyses: Heighway et al, 2002) that S100A2 is very strongly
expressed in the majority of primary NSCLC lesions. In an attempt
to explore whether high-level expression is either normal or
associated with carcinogenesis, we have carried out a series of
immunohistochemical analyses on an independent series of
tumour and multiple matched normal and preneoplastic bronchial
epithelial sites from a panel of NSCLC patients. We have
supplemented this analysis with: a re-examination of transcript
levels in this new series of lesions, a mutation scan of the gene in
primary tumours and tumour cell lines and an investigation of
allele-specific expression in normal and tumour tissue. Finally, by
comparative multiplex RT–PCR (cmRT–PCR), we have examined
the expression of DNp63 in the tissue samples following the recent
suggestion that S100A2 is a target of the DNp63 oncogenic pathway
(Hibi et al, 2003) and bearing in mind that the p63 transcript was
also highlighted in our microarray-generated, tumour over-
represented gene lists (4two-fold in 24%, nine out of 37 patients).
MATERIALS AND METHODS
Patients and cell lines
Tissues from a total of 48 patients with resectable-staged NSCLC
were used in the expression and immunohistochemical (IHC)
analyses (37 men, 11 women, median age 65.3 years, range 30.6–
80.7). Frozen tumour tissue was obtained from all patients and
matched normal lung from all but two patients. A total of 17
patients had stage I disease, 12 stage II and 19 stage III or above.
All tumours were classified according to the standard criteria of
the WHO. There were 20 squamous cell carcinomas, 24
adenocarcinomas, three large cell carcinomas and one poorly
differentiated NSCLC. Matched normal tissues were obtained from
bronchial epithelium at a tumour-free site. Frozen tissues were
kept at  701C. Blocks for immunohistochemistry were fixed in
formalin and embedded in paraffin. For 20 of the patients in this
series, blocks of matched histologically normal bronchial epithelia
from a further five independent, tumour-free sites were also
collected. Tumour DNA samples from a further 38 UK NSCLC
patients, including material derived from samples previously
screened by microarray was scanned for somatic mutations. Lung
carcinoma cell lines: CORL23, CRL5082, DMS53, SKLU1, HTB182,
A549, LUDL1, CORL88 were obtained from ATCC. The analysis of
lung cancer-related gene expression in the clinical samples was
approved by local ethics committees in Bern and Liverpool.
RNA and DNA extraction
Total RNA was extracted from 20 40-mm sections of frozen tumour
and matched normal tissue using a standard TRIzol (Life
Technologies) protocol (Heighway et al, 2003). DNA was extracted
from 10 40-mm frozen sections, using a standard SDS lysis/phenol
extraction procedure (Heighway et al, 2003). Sections of 6mm were
cut adjacent to both RNA and DNA sections and stained with
haematoxylin and eosin to show tumour histology and to estimate
the overall percentage of overt viable tumour cells.
PCR and RT–PCR
PCR reactions of 50ml containing approximately 50ng of DNA,
250ng of each primer, 1 Taq reaction buffer (Roche), 200mM
dNTPs (Roche) and 1U of Taq polymerase were assembled and
cycled 30 times, in a PE Applied Biosystems GeneAmp PCR System
9700 machine, at 581C for 1min, 741C for 1min and 941C for
1min, with an initial denaturation of 2min at 941C and two final
incubations of 581C for 1min and 741C for 3min. Reverse
transcription was performed with the Reverse Transcription
System from Promega, in a 20ml poly-T-primed synthesis using
approximately 500ng of total RNA. RT–PCR reactions were
assembled and cycled as for PCR, except that a 1ml aliquot of
cDNA was used instead of DNA.
Primers
Transcript-specific primers SA21a (50 GAA CTT CTG CAC AAG
GAG CTG) and SA21b (50 AAA GGC ATC AAC AGT CCT GGG)
were used to amplify S100A2 from cDNA and p63F1 (50 AGT GTG
CTG GTA CCT TAT GAG) and p63R3 (50 GTA CTG TCC GAA ACT
TGC TGC T) were used to amplify p63 transcripts. Transcript-
specific primers for the nondifferentially-expressed control gene
amyloid beta precursor protein binding protein (KIAA0228,
Accession number NM_006380) APPBP2F (50 GAA CTG TGT
GCA CTC CTA TTT G) and APPBP2R (50 CCG TGC CAA ATA CAC
TGC ATG T) were used in cmRT–PCR.
Primers pSA21a (50 CTG GCT TGG TGA TGA GTG TAT) and
pSA21b (50 CTC AAA GGC ATC AAC AGT CCT), were used to
amplify the S100A2 gene from DNA for RFLP analysis. Exons 2 and
3 were amplified from tumour genomic DNA for WAVE analysis
using SA2F (50 CAG AAG TGG ATC CTA CAG GCT) and SA2R
(50 ACT GGG GGA GAG ATT TAA CCT G), and SA3F (50 GCT GGC
TTG GTG ATG AGT GTA) and SA3R (50 GGT TAT GGA ACA TCA
CTG AGC A), respectively.
Comparative multiplex RT–PCR
Comparative multiplex (cm) RT–PCR was used to compare levels
of test gene transcripts between normal lung and tumour samples,
as described previously (Heighway et al, 2002; Smith et al, 2003).
Briefly, the test gene transcript was coamplified with a nondiffer-
entially expressed control transcript (APPBP2 – KIAA0228) in the
same reaction. Reaction products were run on 3% agarose gels
containing 0.5mgml
 1 ethidium bromide, in 0.5 TBE and
visualised by UV illumination. Relative expression was quantified
on an Agilent 2100 Bioanalyser using DNA 1000 chips (Agilent
Biotechnologies). To obtain values for S100A2 and DNp63
expression relative to the control transcript APPBP2, peak heights
of the test genes were divided by those of the control gene within
each sample. The comparative value in the patient tumour tissue
was then divided by that from the matched normal to calculate the
fold difference in expression of the test gene in each patient. Where
no test-gene product was seen in normal tissue and where a
product was detected in tumour, the fold-change was therefore
infinite. While in many cases test gene expression was not detected
in normal lung, a differential expression of the test gene of Xtwo-
fold in the tumour was considered to indicate a relative over-
representation of that gene in the tumour. It should be noted that
this procedure is only semiquantitative and does not reflect an
absolute expression level of the test gene mRNA.
RFLP-RT–PCR and RFLP-PCR
A1 0ml aliquot of PCR or RT–PCR product was digested with 5U
of HinfI (NEB) in a 40ml reaction containing 1 manufacturer’s
restriction enzyme buffer at 371C for 3h. Digests were visualised
by gel electrophoresis and quantified by running on DNA 100
LabChips
s in an Agilent 2100 Bioanalyser (Agilent Technologies).
WAVE mutation analysis
PCR products from S100A2 exons 2 and 3 were screened for
mutation using denaturing high-performance liquid chromato-
graphy (O’Donovan et al, 1998) using a WAVE
s system (Model
3500A Transgenomics Limited, Crewe, UK). To account for
possible deletions of 1q21 in tumours preventing heteroduplex
formation, PCR products were mixed 3:1 ratio with PCR product
from normal wild-type DNA. PCR products were denatured at
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y941C and returned to 251C (at 11Cmin
 1) for heteroduplex
formation. Denaturing acetonitrile gradient profiles and melting
temperatures for analysis were determined using Wavemakert 4.1
software (Transgenomics). Exon 2 was analysed at 62.51Co na
gradient of 55% buffer B (Transgenomics; 25% acetonitrile/0.1 M
TEAA) for 4min. Exon 3 was analysed at 601C on a gradient of
56% buffer B for 4min.
Immunohistochemical analysis
Formalin-fixed, paraffin-embedded sections of 5mm were dewaxed
in xylene for 30min, followed by rehydration through a series of
graded ethanols to water. Antigens were retrieved using a 15min
microwave treatment in Vector unmasking solution (10mM
sodium citrate buffer, pH 6). Slides were left to stand in the
unmasking solution for 15min after treatment and then placed
under running water for 5min prior to loading onto a Dako
Autostainer. Endogenous peroxidase was blocked by a 15min
incubation in 3% vv
 1 H2O2. Sections were then incubated for
60min in a 1 in 500 dilution of S100A2 rabbit polyclonal antibody
(Dako). This was followed by detection of specific staining with the
Dako LSAB2 HRP system with DAB (diaminobenzidine) substrate.
Slides were counterstained in Haematoxylin/Scotts tap water and
dehydrated through a series of graded ethanols to xylene. Sections
were mounted in DPX and visualised. In negative control sections,
the primary antibody was replaced with diluent. A tumour which
strongly expressed S100A2 was used as a positive control on all
autostainer runs.
The sections were reviewed by our pathologist (MG) in a blinded
fashion, considering histology, grading of differentiation and
S100A2 staining. Epithelial changes were graded according to the
criteria reviewed by Travis et al, 1999. Squamous metaplasia is the
first clear-cut morphological change in the respiratory epithelium
induced by smoking. We grouped epithelial sites into non-
neoplastic (histologically normal and hyperplastic) and premalig-
nant/noninvasive (metaplastic, dysplastic and carcinoma in situ).
In detail, regarding S100A2 staining the following criteria were
used for cytoplasmic and/or nuclear staining, for the intensity  ,
þ, þþ, þþþand for the frequency 0–5, 5–50, 50–100%. For
data grouping, a tumour (or bronchial site) was considered to be
positive for nuclear and cytoplasmic staining if 45% of the (site:
apical epithelial) cells were scored with a þþ to þþþ
intensity.
Statistical analysis
w
2-analysis was used to compare the frequency of nuclear and
cytoplasmic staining for S100A2 in: normal (normal and
hyperplastic) vs preneoplastic/noninvasive (metaplastic/dysplas-
tic/CIS) epithelia and between squamous cell and adenocarcinoma.
The comparison of tumour expression between RT–PCR and IHC
was carried out using a Mann–Whitney test with fold over-
expression as a continuous variable and staining considered as
positive or negative. Patients were further placed into two groups
according to their S100A2 expression (IHC) and overall survival
and remission duration were analysed by Kaplan–Meier survivor
function estimates.
RESULTS
S100A2 expression in NSCLC
Building on our earlier microarray validation study, we have
further investigated the expression of S100A2 in an independent
series of NSCLC patients. Levels of S100A2 transcript in tumour
samples of this new series were compared to those in matched
normal lung, by cmRT–PCR. An endogenous control transcript
(ABPPBP2) previously identified as not differentially expressed
between normal lung and lung tumours (Heighway et al, 2002) was
used as an internal control transcript. Results of this analysis are
illustrated in Figure 1.
S100A2 expression was detected in the normal tissue of most,
but not all patients. However, most tumours showed an over-
representation of the transcript relative to the matched normal
tissue levels. When cmRT–PCR products were run on an Agilent
Bioanalyser, 35 out of 46 (76%) patients showed a Xtwo-fold over-
representation of S100A2 in their tumour sample compared to
their matched normal lung sample (Table 1).
In certain cases, we detected an additional transcript in the
patients’ tumour sample. By cloning and sequence analysis, we
determined that an additional exon (exemplified by BM016868)
was spliced into this transcript, between exons 2 and 3 (called exon
2A). Using exon-specific RT–PCR, this alternative transcript could
be specifically amplified from a range of tumours but not normal
lung. However, the levels as judged by cmRT–PCR were invariably
low in comparison to the normal exon 2/3 gene product (results
not shown). We therefore excluded further consideration of this
alternatively spliced transcript from this study.
Mutation analysis
It has been suggested that S100A2 is a tumour suppressor gene and
that its expression is downregulated in neoplastic cells. If that were
the case, it is possible that the gene would be the target of somatic
mutational inactivation events. Similarly, while we observed strong
expression in the majority of NSCLC samples, it is possible that
this apparently elevated transcript level was driven by upregulation
of a functionally inactive protein in the tumour cell. Conversely, if
the gene were inappropriately activated in a tumour cell thereby
providing an oncogenic stimulus, at least in some instances this
227 200 222 233 232 226 183 184 223 −ve
208 194 218 216 220 205 230 204 −ve 209
NN N N NN N N N TT T TTTTTT
NN N N NN N N N TT T TTTTTT
S100A2
APPBP2
S100A2
APPBP2
Figure 1 Expression of S100A2 in primary NSCLC. S100A2 transcripts were coamplified with transcripts of a control gene by comparative multiplex RT–
PCR. Representative agarose gels are shown. Transcripts of the gene for APPBP2 were used as the control. N¼normal bronchial epithelial tissue.
T¼NSCLC tissue. Numbers represent anonymised patient numbers. Marker track (extreme left on all agarose gel images) is a FX174/HaeIII digest.
S100A2 expression in bronchial epithelia
SL Smith et al
1517
British Journal of Cancer (2004) 91(8), 1515–1524 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ymight conceivably be achieved by point mutation of the coding
sequence. To explore these different possibilities, we carried out a
mutational screen of the S100A2 coding sequence (which is
contained within exons 2 and 3 of the gene). The two exons were
amplified from the genomic DNA of 36 primary tumour samples
and from eight lung carcinoma cell lines using primers sited within
the adjacent introns. The PCR products were subjected to
heteroduplex analysis using a Transgenomic WAVE system. With
the exception of four samples that were heterozygous for a cSNP
within exon 3 (Figure 2), no traces suggestive of mutation were
obtained from any of the tumours. We therefore conclude that
mutational activation or inactivation of this gene is either rare or
does not occur in NSCLC.
Immunohistochemistry
Having previously demonstrated that the S100A2 transcript and
protein are strongly expressed in tumour cells compared to normal
lung, we sought to examine protein levels in the independent
patient series. In addition to examining expression in normal and
tumour tissue in this series, we also sought to examine expression
in relation to preneoplasia, histology, and clinical outcome, in an
attempt to further characterise the expression of S100A2 in
NSCLC. Tumour and matching normal tissue was available from
48 NSCLC patients in the independent series. In addition, six
bronchial sites distant from the primary tumour, were analysable
for 20 of these patients. All tumours and non-tumour sites were
investigated for S100A2 expression. Bronchial epithelia for each
non-tumour site were graded (by our pathologist: MG) according
to the degree of apparent histological abnormality into: normal,
hyperplastic (basal cell and goblet cell), metaplastic, dysplastic or
carcinoma in situ (CIS). Staining was assessed as described in
Materials and Methods.
Of the 48 tumour sections, 47 were analysable (one sample
was rejected as highly necrotic). A total of 29 out of these
47 tumours (62%) strongly expressed S100A2 either in the nucleus
(26 out of 47) or the cytoplasm (28 out of 47). Three tumours
showed exclusively cytoplasmic staining with one showing
exclusively nuclear staining: 25 out of 47 lesions therefore
demonstrated staining in both compartments (see Figure 3 for
representative images of staining). Squamous cell lesions were
more likely to be positive than adenocarcinomas (nuclear
P¼0.0015, cytoplasmic P¼0.0046: Table 2A), but we failed to
detect a correlation between staining levels and overall survival or
between staining and smoking history. This is perhaps not
surprising given the small sample size. Although the RT–PCR
and IHC assays measure slightly different qualities of gene
expression and are performed on sections from different areas of
the primary tumour, there was a good correlation between the
tumours scored as positive and negative for strong S100A2
expression (Po0.0003).
Bronchial epithelial sites were identified in 117 separate sections
from 20 patients. The majority of the differentiated epithelial cells
in the normal lung did not express S100A2 (hence, the lower levels
recorded by RT–PCR, Western and microarray analyses of normal
lung tissue). However, strong nuclear staining of the basal
epithelial cells was apparent in the overwhelming majority of both
normal and other (hyperplastic/metaplastic/dysplastic/CIS) sites
examined (97%, 113 out of 117, Figure 3) and therefore most likely
represents a normal pattern of S100A2 expression for this cell type.
Basal cell cytoplasmic staining was also commonly present (79%,
93 out of 117 sites). In contrast, the apical cells of histologically
normal bronchial epithelia were generally negative for S100A2
expression, with only a single site (2%, one out of 46) showing
strong (nuclear) staining (Table 2). As the degree of tissue disorder
increased, so did the frequency with which lesions stained for
S100A2 with: 16% (nine out of 55) of hyperplastic and 62% (eight
out of 13) of preneoplastic (metaplasia, dysplasia, CIS) lesions
showing strong nuclear staining (Po0.0001). Sites were classified
as non-neoplastic (normal, hyperplastic) and preneoplastic. Apical
cell nuclear and cytoplasmic staining was more commonly found
in preneoplastic/preinvasive (eight out of 13, six out of 13)
compared to non-neoplastic (10 out of 101, nine out of 101)
epithelial sites (Table 2B; Po0.001).
Table 1 Semiquantitative analysis of S100A2 and DNp63 transcript
expression in NSCLC patients
Patient S100A2 p63
173 50.0 
174 1.1  1.3
175 7.8 
176 7.5  4.6
179 2.2  1.8
182 850.6  23.9
183 6.0  2.6
184 2.9  0.2
186 1.3  1.9
187 0.2  0.7
189 0.3 
193 7.8  57.7
194 32.0  21.6
195 11.6  21.9
196 0.4  0.6
197 0.8  3.4
198 0.9  0.2
200 20.0  8.2
204 3.0  40.1
205 276.7  95.5
206 7.1 
207 Infinite  Infinite 
208 10.1  73.0
209 21.4  115.2 
210 Infinite  19.5
211 2.4  3.8
214 79.3  22.2
216 13.9  63.9
217 1.4  1.7
218 27.0  20.3
219 7.5  75.4
220 3.0 
222 323.6  2.1
223 28.6  0.2
224 50.6  633.0 
226 6.5  1.7
227 3.9  11.4
229 1.4  0.4
230 25.0  67.8
231 10.3  10.8
232 3.4  1.5
233 4.5  1.0
234 0.2 
235 2.9  3.0
236 1.6  0.2
237 14.0  6.6
S100A2 or DNp63 transcripts were coamplified with a control gene transcript from
normal and tumour tissue of NSCLC patients, by cmRT–PCR. Reaction products
were run on an Agilent bioanalyser. Peak heights of control and test genes were
compared for each patient to generate a semiquantitative value for the fold
expression of the test gene transcript in the tumour sample compared to matched
normal lung. Red boxes indicate where a patient showed Xtwo-fold expression of
the test transcript in the tumour sample compared to normal lung. Black boxes
indicate a otwo-fold expression and a white box indicates no data for that patient.
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Unequal expression from the two alleles of an over-represented,
nonimprinted autosomal gene in a tumour (allelic expression
imbalance or AEI) may reflect either genomic damage events such
as chromosomal translocation or point mutation or it may indicate
allele-specific epigenetic alteration involving DNA methylation or
histone deacetylation. The observation of tumour AEI is therefore
consistent with the hypothesis that the overexpression of a
particular gene is causally linked to neoplasia (Ratschiller et al,
2003).
A PCR-RFLP analysis was used to determine the relative
contribution of the two S100A2 alleles to expression in our NSCLC
patients. Results were quantified by Agilent Bioanalysis. Exon 3
encodes a rare cSNP (0.95/0.05) that can be used to assess the
allelic balance in DNA and the corresponding allelic expression
balance in cDNA. Typing of genomic DNA revealed that five out of
the 46 patients investigated in the expression analysis were
heterozygous for the cSNP. S100A2 was scored as over-represented
in each of these lesions by cmRT–PCR. All patients showed
balanced biallelic expression in the normal tissue samples.
However, one patient (218) showed marked allelic expression
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Figure 2 Identification of S100A2 exon 3 polymorphism. (A) WAVE analysis of exon 3 in lung tumours: 5 and 6 left panel, 13 and 14 right panel. Arrows
identify heteroduplex fragments. (B) RFLP analysis of exon 3 in lung tumours 13, 14, 5 and 6. Digestion with HinfI reveals the presence of the polymorphism
in tumours 5 and 14.
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yFigure 3 Immunohistochemical analysis of S100A2 expression in NSCLC and normal lung tissue. S100A2 is expressed strongly in the nucleus and also
generally in the cytoplasm of basal epithelial cells of normal tissue but it is generally not detectable in histologically normal apical epithelial cells (A). Intense
nuclear and cytoplasmic staining of the tumour cells is seen in positive tumours (F). Stromal cells are negative (A–F). However, a small number of
hyperplastic epithelia show strong nuclear/cytoplasmic expression of S100A2 in the apical differentiated cells (B). The remaining panels show preneoplastic
epithelial lesions, which commonly show strong staining for S100A2. The flanking histologically normal epithelia in the metaplasia, dysplasia and CIS panels
show a more typical expression pattern.
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yimbalance in the tumour compared to the matched normal lung
sample (Figure 4). As allelic imbalance (AI) at the DNA level was
not detected in this sample, this suggested that the strong
expression seen was a consequence of upregulation of one
chromosomal allele in the tumour. The other four patients all
showed tumour allelic expression balances that approximated the
allelic balance of the tumour DNA.
DNp63 expression in NSCLC
S100A2 has recently been reported to be a target of the
transcriptional activator DNp63 (Hibi et al, 2003), which is
encoded by the TP73L gene. Bearing in mind this observation,
the fact that four of five of the informative tumours showed strong
biallelic S100A2 expression and considering that the products of
Table 2 Expression of S100A2 (n¼114 sites: 101 non-neoplastic, normal and hyperplastic, and 13 preinvasive)
Nuclear Cytoplasmic
Tumours Negative Positive Negative Positive
(A) Expression pattern of S100A2 across a series
of 47 primary NSCLCs
a
Adenocarcinoma 15 9 14 10
Large cell 1 1
LCNEC 2 2
NSCLC undifferentiated 1 1
Squamous cell 3 16 3 16
Apical epithelial sites
(B) Association of S100A2 expression of the apical
part of the epithelium with histology (n¼114
sites: 101 non-neoplastic, normal and
hyperplastic, and 13 preinvasive)
b
Normal 45 1 46 0
Hyperplastic (goblet/basal) 46 9 46 9
Metaplasia/dysplasia/CIS 5876
aWhile there was a strong bias towards positive staining in squamous cell carcinomas, a significant fraction of adenocarcinomas also strongly expressed the gene.
bAll histologically
normal sites but one showed a consistent staining pattern of exclusively basal cell staining. Preneoplastic sites from individual patients showed strong expression. Apical cell
staining was predominantly related to the histological state of the tissue and was not consistent for any patient across all non-neoplastic sites analysed.
DNA cDNA
Normal Tumour Normal Tumour
218 1.2 1.3 1.3 5.5
219 1.1 1.8 1.0 0.9
220 1.1 0.7 1.2 0.6
224 1.3 1.1 1.0 1.1
232 1.1 1.0 0.8 0.8
218
NT N T
DNA cDNA
NT N T N TNTNTNTN T
NT NT
DNA cDNA DNA cDNA DNA cDNA
DNA cDNA
219 220 224
232
A
B
Figure 4 RFLP-cmRT–PCR and –PCR analysis of S100A2 in NSCLC. A region of the S100A2 gene containing a cSNP was amplified from DNA and
cDNA by PCR and RT–PCR, respectively. Reaction products were digested with HinfI and run on a 3% agarose gel (A). Products were also run on an
Agilent bioanalyser DNA 1000 chip. Peak heights of the noncutting allele (upper product on the agarose gel) were divided by those of the cutting allele
(lower band on agarose gel) to give a relative value for the cutting allele compared to the noncutting allele (B). Patient 218 shows an imbalance in the cDNA
(allelic expression imbalance) of the tumour sample compared to the normal tissue.
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24% (nine out of 37) of samples in our microarray analysis, we
examined the expression of this gene in this independent NSCLC
series. The initial microarray data suggested that S100A2 was also
over-represented in eight out of nine of these particular tumours,
but there were a further 10 lesions in which S1000A2 was strongly
expressed in the apparent absence of TP73L transcript over-
representation and one lesion in which TP73L was marginally
increased with no apparently corresponding upregulation of
S100A2. We therefore sought to validate these observations on a
second set of tumours by a second technique.
RT–PCR analysis (not shown) was consistent with the DNp63
transcript being the predominantly spliced gene product in
tumour tissues. Strong TP73L expression was not detected in the
normal lung (Figure 5). However, 23 out of 46 (50%) of patients
showed over-representation of DNp63 in the tumour sample (see
Figure 5 and Table 1). This expression correlated with S100A2
levels in 25 out of 40 patients (63%). However, six patients (15%)
showed overexpression of S100A2 but not DNp63, and one out of
40 patients (2.5%) showed overexpression of DNp63 but not
S100A2, indicating that other mechanisms in addition to DNp63
transcription are at least partly responsible for the high-level
expression of S100A2 in tumour tissue.
DISCUSSION
The detection and effective treatment of early stage disease is likely
to dramatically improve survival rates for NSCLC patients. We
have previously used cDNA microarray analysis to identify genes
which are strongly expressed in tumour over normal tissue with
the aim firstly of evaluating the involvement of such sequences in
disease pathology and secondly, of investigating their possible
utility as new diagnostic and/or therapeutic targets. Using this
approach, we have demonstrated that S100A2 gene products are
over-represented in the tumours of most NSCLC patients
compared to matched normal lung tissue (Heighway et al, 2002).
Surprisingly, based on a number of studies of gene expression,
S100A2 is generally considered to be a tumour suppressor gene. In
particular, using cell line models of the disease process, diminished
expression has previously been reported to occur in lung cancer
(Feng et al, 2001). Given the contradictory nature of our data, we
therefore sought to further characterise S100A2 expression in an
independent (from the microarray analysed) series of NSCLC
patients, and to further investigate the role of S100A2 in early
preneoplastic bronchial lesions.
Using semiquantitative RT–PCR and essentially confirming our
earlier observations, 76% of NSCLC patients examined showed a
two-fold or greater over-representation of S100A2 transcripts in
their tumour sample compared to matched normal lung. S100A2
transcripts were consistently detected in normal tissues, but were
present at much lower levels compared to tumour samples.
Increased expression of the transcript appeared to be accompanied
by increased protein expression and using IHC, 62% of tumours
showed strong expression of S100A2 protein. The high levels of
S100A2 were confirmed through Western analysis (not shown) of a
subset of lesions with a second monoclonal antibody identical to
that used by Feng et al (2001). Normal lung tissues were scored as
negative for S100A2 expression (only one out of 46 showed
positive staining) as most of the tissue stained negatively.
However, strong nuclear and cytoplasmic staining was seen
consistently in the basal cells of the bronchial epithelium. The
other histologically normal cells of the lung including the
columnar epithelia of the airways do not appear to express S100A2.
A similar pattern of expression for S100A2 has been reported in
other tumour types. Specifically, the gene is expressed in the basal
and parabasal cells of the epithelial layer of normal skin and in
skin tumours (Shrestha et al, 1998; Park and Min 2003).
Expression in normal squamous laryngeal epithelium and in
laryngeal squamous cell carcinoma has also been reported
(Lauriola et al, 2000). Furthermore, this expression was strictly
associated with cytokeratins 14 and 17, which are markers of basal
and parabasal cells in normal laryngeal epithelium (Van der
Velden et al, 1997). These observations suggest that in normal
epithelia, the expression of S100A2 is associated at least in some
instances with multipotent populations of cells.
In this study, we have investigated S100A2 expression in
histologically normal and hyperplastic epithelia and preneoplastic
(metaplasia, dysplasia, CIS) lesions. We found that as the degree of
preinvasive pathology increased, so did the frequency with which
lesions stained for S100A2. Whereas, in normal epithelia, basal
cells were positive and apical cells were negative for S100A2
expression, in some hyperplastic epithelia (16%) and the majority
of preneoplastic (62%) epithelia, both basal cells and apical
epithelial cells showed positive staining. The basal epithelia cell is a
multipotent reserve cell which can differentiate into each of the
mature cell types of the bronchial epithelium. Our analysis of the
patterns of expression in normal tissue sections suggests that
S100A2 expression should normally be downregulated in this
differentiation process. Our observation of high levels of expres-
sion in preneoplastic regions suggests that this has not occurred,
either coincidentally or pathologically in the cells of these lesions.
The identification of genetic damage affecting the S100A2 gene
would add weight to the argument that this sequence is causally
involved in neoplasia. Similarly, if this gene were a genuine tumour
suppressor, we might expect to find coding sequence mutations
inactivating function. We did not find any evidence of point
mutation within the S100A2 coding sequence, and concluded that
such an event is either rare or nonexistent in NSCLC. We have
previously shown, using comparative multiplex PCR, that ampli-
fications of the S100A2 gene in NSCLC are rare (Heighway et al,
2002), and we have confirmed this observation in the current
patient series (data not shown). However, screening normal DNA
samples, we were able to identify five patients who were
heterozygous for a coding sequence SNP within exon 2 of the
S100A2 gene. The matching tumour DNA for all five patients
showed no evidence of allelic imbalance (AI) at this locus. We did
however detect a marked allelic expression imbalance (AEI) in the
tumour of one patient compared to their matched normal lung.
This patient also showed strong expression of S100A2 in the
tumour tissue. The expression imbalance is indicative of a cis-
located DNA damage or modification event which results in the
upregulation of one parental allele. This event could be a
chromosomal translocation or a promoter mutation or an allelic
216 218 222 223 224 226 230 231 233
NTNTNTNTNTNTNTNTNT −ve
APPBP2
Np63
Figure 5 Expression of DNp63 in primary NSCLC. DNp63 transcripts were coamplified with transcripts of a control gene by comparative multiplex RT–
PCR. Representative agarose gels are shown. Transcripts of the gene for APPBP2 were used as the control. N¼normal bronchial epithelial tissue.
T¼NSCLC tissue. Numbers represent anonymised patient numbers.
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overexpression of the S100A2 transcript. Methylation differences
within the S100A2 gene locus have previously been reported
(Wicki et al, 1997) and it is possible that an aberrant lack of
methylation of one parental allele could lead to inappropriate
expression of the S100A2 gene in tumour tissue.
We have previously shown that p63 transcripts are over-
represented in NSCLCs using cDNA microarray analysis
(Heighway et al, 2002). In this study, we confirmed that the
over-represented transcript is the DNp63 alternatively spliced gene
product and that this is strongly expressed in 50% of tumours
compared to normal lung. S100A2 has recently been reported
to be a target of DNp63 (Hibi et al, 2003) a transcriptional
activator. Overexpression of DNp63 in NSCLC has also been
reported by Massion et al (2003), who also demonstrated that
amplification of the p63 gene is an early event in lung cancer
development. Interestingly, they also showed that p63 was strongly
expressed in the basal cells of the normal bronchial epithelium.
Therefore, one trans-acting mechanism whereby S100A2 may be
overexpressed in NSCLC might be upregulation by DNp63.
Although DNp63 expression correlated well with S100A2 expres-
sion – in that tumours strongly expressing TP73L tended to
strongly express S100A2 – there was not an exact correlation.
Specifically, while all but one of the tumours in both independent
series (microarray, RT–PCR) that strongly expressed DNp63
coexpressed S100A2, there were a number of tumours (10 out of
37 and six out of 40, respectively) that showed over-representation
of S100A2, in the apparent absence of DNp63 elevation. We
therefore conclude that overexpression of DNp63 transcripts may
explain S100A2 overexpression in some cases of NSCLC, but that
this is probably not the only mechanism involved. While the allele-
specific expression data presented support this idea, further cell-
by-cell analysis of the level of S100A2 transcription in relation to
the level of functional DNp63 protein would be needed to confirm
this hypothesis.
Interestingly, although many adenocarcinomas (10 out of 24)
did express S100A2, we found that expression correlated more
closely with a squamous histology (16 out of 19). S100A2 is located
within the epidermal differentiation complex (EDC), on chromo-
some 1q21 (South et al, 1999), and has been associated with
squamous cell differentiation (Xia et al, 1997; Shrestha et al, 1998).
The strong correlation with a squamous histology would perhaps
suggest that S100A2 is functionally linked to the squamous
phenotype. However, many lung adenocarcinomas and other
nonsquamous cancers (for example, gastric carcinomas) strongly
express S100A2. Squamous cell lung carcinomas tend to be
centrally located, arising in a major airway, from a component
of the bronchial epithelium. Lung adenocarcinomas can form
centrally but they tend to be associated with the epithelia of the
peripheral airways. Recently, it has been suggested that adeno-
carcinoma can be classified into two distinct subtypes on the basis
of gene expression patterns (Bhattacharjee et al, 2001; Garber et al,
2001). These two subtypes may be delineated by TTF (thyroid
transcription factor)-1 expression, which is a lineage marker for
peripheral airway cells, including type I and II pneumocytes
(Yatabe et al, 2004). Interestingly, TTF-1 expression in adenocar-
cinoma is inversely correlated with expression of maspin
(Kobayashi et al, 2004), which we have previously shown to be
tightly restricted to basal cells of the bronchial epithelium in
normal lung (Smith et al, 2003). Normal alveoli do not express
S100A2. Taken together, these observations suggest that squamous
cell carcinomas that are generally positive for S100A2 expression
and S100A2 positive adenocarcinomas may arise either from the
multipotent basal cells of the bronchial epithelium or else from a
stem cell progenitor which expresses this and other tumour-
associated genes (maspin, DNp63). S100A2/maspin-negative
adenocarcinomas may similarly arise from such multipotent
progenitors, in which case they would represent a clonal lesion more
closely associated with the expression pattern of a differentiated
peripheral airway cell or else they may actually arise from such a
cell. Such a model would suggest that tumour S100A2 expression is
related to the expression pattern of the cell-type of origin and not
simply a characteristic of squamous cell differentiation.
The function of S100A2 remains unknown. It is widely thought
to be a tumour suppressor (Lee et al, 1992; Wicki et al, 1997;
Nagy et al, 2001). However, S100A2 is strongly expressed in
many tumours (Villaret et al, 2000; Hough et al, 2001; El-Rifai
et al, 2002). It is also expressed in regenerative hyperplasia
of keratinocytes and is active psoriasis (Xia et al, 1997), which
are characterised by increased signal transduction through the
cErbB family of receptor tyrosine kinases (Stoll et al, 1997).
Activation of the EGF receptor, which is mutated in primary
lung cancers (Lynch et al, 2004) selectively stimulates S100A2
gene expression, at the transcriptional level (Stoll et al, 1998).
EGFR-dependent S100A2 expression in keratinocytes is thought
to correlate with proliferation (Xia et al, 1997) but only in
cells committed to squamous differentiation. This is consistent
with the observation that expression of S100A2 in psoriatic
skin occurs in the supra-basal epithelial layers. However, the
protein is expressed consistently at high levels in the normal
basal epithelial cells of the airways, which are generally in a
nonproliferating state. S100A2 expression in this multipotent
cell type is therefore unlikely to be linked to a cause or effect
of commitment to a squamous cell lineage and must serve
some other function, perhaps one associated with some aspect of
self-renewal.
A number of genes have recently been shown to be expressed
strongly in tumours, preneoplastic bronchial lesions and in the
normal multipotent basal epithelial cells of the airway: examples
include S100A2, TP73L and SERPINB5. Similarly, basal cell
markers such as cytokeratin 17 and 19 are among the most
frequently expressed genes in NSCLC tissues (Heighway et al,
2002: for lesion-by-lesion detail see http://www.roycastle.org/
research/presentations.htm). Such observations perhaps lend
weight to the hypothesis that tumours arise directly from a
multipotent or stem cell component of the epithelium. One
possibility is that a significant fraction of tumour over-represented
genes are normally inactivated as such multipotent stem cell (like)
cells differentiate, perhaps (as has been implied for SERPINB5) by
promoter methylation. The unusual expression of genes like
SERPINB5 and S100A2 in differentiated preinvasive cells (and
subsequently in tumours) may therefore indicate that a failure to
appropriately inactivate stem cell-associated sequences, perhaps
by epigenetic modification, is an important proneoplastic mechan-
ism. The wider exploration of tumour expression data in this
context might therefore refine our understanding of the origins of
neoplasia.
Taken together, the observations presented are consistent with a
direct role for S100A2 in bronchial neoplasia. Our failure to
identify any inactivating mutations in this gene fails to support the
argument that the sequence is a tumour suppressor in the lung.
Further functional analysis will be required to determine whether
S100A2 might represent a novel therapeutic or diagnostic target in
early lung cancer.
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